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Dr Anil Hingorani (Brooklyn, NY). I want to congratulate
you on analyzing such a large data set because I think it is the only
way we are going to be able to get at some of these questions.
However, when you are dealing with these large data sets, one
common problem is that you really can’t get at some of the details.
First, I don’t know how you ended up with the data set from
California, being from Johns Hopkins, but I congratulate you on
acquiring it and analyzing it. One thing I am really concerned
about when I read over the abstract is that there were only five
hospitals in the last group that met both standards. Whenever you
have such a large data set and only five hospitals in one group and
you’re trying to derive data from there, I think some of your
conclusions may not be as solid.
This is still a retrospective database, and the prospective data
that has looked at aneurysms has already shown that -blockers are
quite clearly beneficial in perioperative outcome in terms of mor-
tality, and probably long-term survival of these patients, irrespec-
tive of whether they have coronary artery disease. What I am
actually more interested in seeing is whether or not some of the
other retrospective data that have suggested statins may be useful
in these patients, which was not addressed in these groups but your
group has looked at before.
I want to congratulate you on analyzing such a large data set.
I think it was a valiant attempt. But the fact that there were only five
hospitals in the last group that met both standards raises some
questions in the fact that there are only 25 hospitals in one group,
and 32 hospitals in the other group, still leads me to still question
some of the conclusions.
Dr Benjamin Brooke. This analysis was focused on California
hospitals alone for a number of different reasons. For one, Leap-
frog was rolled out in phases, and California was one of the few
states targeted in the first rollout period beginning in 2000 to
2001. Second, this state contained the largest number of hospitals
targeted by the initiative overall, so it offered us the most robustpopulation from which to generalize our results to the broader
community. The fact that only five hospitals in this state met both
Leapfrog criteria should not come as a surprise, given the results of
previous studies showing that only a small number of hospitals in
California are able to meet Leapfrog’s volume criteria. While
outcomes at these hospitals were significantly improved compared
with control hospitals, you are correct that we need to be careful
about extrapolating too much from limited data. To address these
limitations, we plan to do future analyses that measure the clinical
impact of Leapfrog standards for AAA repair using a large nation-
wide data set among Medicare beneficiaries.
You raise another excellent point about the fact that we are
evaluating the effect of implementing known evidence-based stan-
dards such as -blocker use. But one of the main reasons for doing
this analysis is to address the question: If the evidence is based on
well-designed randomized trials and is already out there, why
aren’t more hospitals standardizing -blocker use during elective
AAA repair? Indeed, our analysis was not designed to evaluate the
efficacy of Leapfrog standards on elective AAA repair; its primary
intent was to look at their effectiveness on a population basis.
Finally, you are absolutely correct about the evidence for statin
use, and I agree that Leapfrog should consider this process measure
as another evidence-based standard for hospitals performing elec-
tive AAA repair.
Dr John Blebea (Philadelphia, Pa). I am a bit concerned
about your conclusions. It appears too simplistic to ascribe out-
comes of AAA repair to only these two variables. I would propose
that the use of -blockers and volume may be an associated variable
but possibly not be a causal one. One could hypothesize that larger
hospitals would be more interested in complying with Leapfrog
standards compared with smaller hospitals. Additionally, it is pos-
sible that hospitals with less prevalent -blocker usage had a larger
percentage of patients with COPD who would therefore not be
given -blockers but would be at higher risk for surgical morbidity
and mortality. Therefore, these two variables alone may not be
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with improved clinical results. Since you have demonstrated that
EVAR vs open surgery has a very large positive impact on mortal-
ity, have you done a multivariate analysis to better determine
possible causal relationships?
Secondly, is there a significant difference in outcome predict-
ability using -blockade, volume, or a combination of both factors?
It appeared that the results were similar or was one single variable
more important?
Dr Brooke. You made an excellent point about the different
types of patients that may be treated in hospitals meeting Leapfrog
standards for AAA repair versus hospitals that don’t meet these
criteria. Indeed, we considered using a multilevel or hierarchal
model for this analysis, which would allow for adjustment of both
patient-level and hospital-level confounders and help risk stratify
the types of patients that are being treated at different hospital
groups. However, a multilevel analysis becomes more complicated
to interpret and would require more observations among hospitals
meeting both Leapfrog standards. We focused on hospital-level
outcomes because we were looking at effectiveness of Leapfrog
standards for AAA repair on a population basis, and for process
measures like -blocker usage, you don’t have patient-level data;
only self-reported hospital data stating whether they comply with
that standard or not.
As far as doing a multivariate analysis, we in fact adjusted for
hospital level variables using Poisson regression models for each of
the Leapfrog hospital groups. Because we stratified outcomes by
the type of procedure, an EVAR variable wasn’t adjusted for in thisregression model. However, we adjusted for all the other hospital-
level variables, such as number of floor or ICU admissions, number
of beds, teaching status, et cetera, and consistently found in-
hospital mortality to be lower for hospitals meeting Leapfrog
standards.
In regards to your last comment about measuring the inde-
pendent effect of -blocker vs volume in a multivariable analysis,
while the reported outcomes were obtained by comparing hospi-
tals meeting individual Leapfrog standards to control hospitals in
separate models, similar results were obtained when all Leapfrog
standard variables were included in the same model. We chose to
develop separate multivariate models for each Leapfrog standard
due to concerns about the collinearity of similar variables in a single
model.
Dr Ali F. AbuRahma (Charleston, WV). Did you look into
the impact of endovascular procedures in these hospitals on the
length of stay for the open repair? I just noticed in our institution
that the people who do an open surgery start to release their
patients even much earlier so they will have a favorable outcome
against the endovascular repair. Did you notice the same in your
experience, sir?
Dr Brooke. While there was a very slight trend in reduction of
length of stay for the hospitals that met both Leapfrog standards,
you really couldn’t say there was any difference given the variance.
So no, we didn’t see any temporal changes for length of stay among
open AAA cases. It was only for endovascular AAA repair cases in
our population.
